Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
{{output}}
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval has added yet another ... ...
